Lonza to establish multi-product fill and finish line in China
The new production line at Guangzhou site will supply global and domestic companies with clinical and commercial batches
As part of its continued investment in China, Switzerland-headquartered CDMO Lonza has announced plans to establish drug product manufacturing capabilities at its Guangzhou, China site.
The new investment will see the company install an aseptic drug product fill and finish production line at the 17,000-m2 cGMP mammalian facility, which only began operations in Q2 this year.
Lonza has said the new production line, which is expected to deliver its first cGMP batch later this year, will significantly expand the site's capabilities, supporting global and domestic customers with supply for clinical trials and commercial batches in China.
In line with the company's strategy to provide integrated end-to-end solutions, the introduction of drug product manufacturing at Guangzhou will provide a combined drug substance and drug product manufacturing service offering.
The sterile, multi-product fill and finish line will support liquid and lyophilized products. The installation is expected to be completed in 2022 and will create more than 150 new positions.
To facilitate the expansion in China, Lonza also plans to expand the footprint of its global Drug Product Services hub in Basel (Switzerland), which supports drug product capabilities across the company's global network by providing formulation development and process development.
Related News
-
News Pharma Supply Chain People Moves
The latest appointments and promotions across the pharmaceutical supply chain. -
News Biosimilars save patients $11B annually, but barriers to adoption remain in US market
Biosimilars introduce competition into the biologics market, driving down prices and increasing patient access. -
News WHO recommends use of two monoclonal antibody treatments against Ebola
The health body recommended use of treatments by Regeneron and Ridgeback Bio -
News Sharp seeks greater foothold in Chinese market through ClinsChain partnership
Sharp hopes teaming up with clinical service provider ClinsChain will open the door to the Chinese market -
News GSK spins off consumer arm Haleon in biggest European listing for a decade
Haleon becomes the world’s biggest consumer health business, but debuted with a lower-than-expected valuation -
News SIGA reports $28M worth of new orders for monkeypox antiviral
The company has seen a sharp uptick in orders for its oral treatment as monkeypox cases rise globally -
News New CPHI report looks at CDMO outsourcing and partner selection
In The Future of Outsourcing - Strategies for Partner Selection, experts from across the pharma industry look at current trends impacting the contract services landscape and gauge the merits and drawbacks of the most common outsourcing strategies ... -
News CureVac files patent infringement lawsuit against BioNTech over mRNA technology
Company is seeking ‘fair compensation’ for alleged infringement of intellectual property rights relating to the use of mRNA tech to create the Pfizer-BioNTech COVID-19 vaccine
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance